Latest Breaking News On - Kiniksa pharmaceuticals ltd - Page 9 : comparemela.com

Kiniksa Pharmaceuticals, Ltd (NASDAQ:KNSA) CFO Mark Ragosa Sells 12,000 Shares

Kiniksa Pharmaceuticals, Ltd (NASDAQ:KNSA) CFO Mark Ragosa Sells 12,000 Shares
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

Mark ragosaSphera funds managementKiniksa pharmaceuticals ltdKiniksa pharmaceuticals stock performanceNews ratings for kiniksa pharmaceuticals dailyKiniksa pharmaceuticalsGoldman sachs group incGet free reportCapital managementSachs groupStreet corpFunds managementWoodline partnersKiniksa pharmaceuticals daily

Kiniksa Pharmaceuticals: Early 2024 Corporate Update A Mixed Bag (NASDAQ:KNSA)

Kiniksa Pharmaceuticals: Early 2024 Corporate Update A Mixed Bag (NASDAQ:KNSA)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesKiniksa pharmaceuticals ltdKiniksa pharmaceuticalsNew year

Kiniksa Pharmaceuticals (KNSA) Provides Corporate Update

Kiniksa Pharmaceuticals (KNSA) Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sanjk patelKiniksa pharmaceuticals ltdKiniksa pharmaceuticalsChief executive officerDisease activity scoreUsingc reactive proteinSecondary efficacy endpointMean differenceLeast squaresRheumatoid factorHealthcare conference

Kiniksa Pharmaceuticals, Ltd : Kiniksa Pharmaceuticals Provides Corporate Update

Kiniksa Pharmaceuticals, Ltd : Kiniksa Pharmaceuticals Provides Corporate Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Sanjk patelRachel frankRegeneron pharmaceuticals incEuropean commissionKiniksa pharmaceuticals ltdExchange commissionDrug administrationChief executive officerDisease activity scoreUsingc reactive proteinSecondary efficacy endpointMean differenceLeast squaresRheumatoid factorHealthcare conferenceRegeneron pharmaceuticals

Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST® 2023 net product revenue grew ~90% year-over-year to $233.1 million – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart Phase 2.

Rachel frankSanjk patelGlobenewswire incEuropean commissionDrug administrationKiniksa pharmaceuticals ltdExchange commissionRegeneron pharmaceuticals incAbiprubart phaseChief executive officerDisease activity scoreUsingc reactive proteinSecondary efficacy endpointMean differenceLeast squaresRheumatoid factor